is a recently discovered protein-coding gene. Here, pan-cancer analysis was conducted to determine the expression patterns of and its impact on immune response, gene mutation, and possible molecular biological mechanisms in different tumors, together with investigating its potential usefulness for cancer prognosis. Data on expression and mutations were downloaded from TCGA and GTEx databases. Clinical survival data from TCGA were used to analyze the prognostic value of . TIMER and ESTIMATE algorithms were used to assess correlations between and tumor-infiltrating immune cells, immune cytokines, and immune scores. BOLA2B was found to be highly expressed at both mRNA and protein levels in multiple tumors, where it was associated with worse overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in all cancers apart from ovarian cancer. was also found to be positively correlated with copy number variation (CNV), and mutations in , and were found to influence expression. Post-transcriptional modifications, including m5C, m1A, and m6A, were observed to regulate expression in all cancers. Functional analysis showed that was enriched in pathways associated with iron-sulfur cluster formation, mTOR-mediated autophagy, and cell cycle inhibition. Decreased expression induced the proliferation of breast cancer cells and G2/M cell cycle arrest. was found to be highly expressed in malignant tumors and could be used as a biomarker of poor prognosis in multiple cancers. Further investigation into 's role and molecular functions in cancer would provide new insights for cancer diagnosis and treatment.